Amedisys, Inc. (NASDAQ:AMED – Free Report) – Stock analysts at Leerink Partnrs raised their FY2026 earnings per share estimates for shares of Amedisys in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now forecasts that the health services provider will earn $5.06 per share for the year, up from their prior estimate of $4.53. The consensus estimate for Amedisys’ current full-year earnings is $4.43 per share.
Amedisys Trading Up 0.1 %
Amedisys stock opened at $92.50 on Monday. Amedisys has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of 36.71, a P/E/G ratio of 1.84 and a beta of 0.72. The company has a 50 day moving average price of $89.41 and a 200 day moving average price of $93.96.
Institutional Trading of Amedisys
A number of institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its holdings in Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new position in shares of Amedisys in the 4th quarter valued at approximately $38,000. Versant Capital Management Inc lifted its holdings in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares during the last quarter. KBC Group NV bought a new stake in Amedisys during the third quarter worth approximately $63,000. Finally, Venturi Wealth Management LLC grew its holdings in Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after purchasing an additional 779 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
- Five stocks we like better than Amedisys
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- Upcoming IPO Stock Lockup Period, Explained
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Canadian Penny Stocks: Can They Make You Rich?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.